In the complaint, White River said some of its contract pharmacies have been denied Novo Nordisk’s products through the hospital’s 340B accounts. The drugmaker disagreed with White River but said “the 340B program has been the subject of significant and well-documented abuses.”
“Novo Nordisk continues to support the 340B drug program so that uninsured and vulnerable patients continue to have access to outpatient drugs,” a spokesperson told Becker’s.
The Arkansas Insurance Department Rule 123, which was implemented Sept. 30, states drugmakers cannot “exclude a pharmacy from a network on the basis of a pharmacy’s participation in 340B pricing.”
The alleged restrictions have cost White River about $1 million, according to the complaint.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
